Showing results (261-270 of 653) with videos related to
Sort By:
Pageof 66
Annals of Surgical Oncology|September 26, 2008
Lymphovascular invasion and lobular histology are associated with increased incidence of isolated tumor cells in sentinel lymph nodes from early-stage breast cancer patientsElizabeth A Mittendorf, Aysegul A Sahin, Susan L Tucker, et al.Breast Cancer Research : BCR|May 25, 2012
Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapyAbigail S Caudle, Tse-Kuan Yu, Susan L Tucker, et al.Cancer|April 19, 2012
Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancerMichelle M Kim, Shaheenah Dawood, Pamela Allen, et al.Journal of Immunotherapy and Precision Oncology|June 6, 2022
Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic CholangiocarcinomaTimothy P DiPeri, Mehmet Demirhan, Daniel D Karp, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2011
Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancerLeonel F Hernandez-Aya, Mariana Chavez-Macgregor, Xiudong Lei, et al.Annals of Surgical Oncology|August 18, 2004
Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapyJeannie Shen, Vicente Valero, Thomas A Buchholz, et al.Cancer Chemotherapy and Pharmacology|June 12, 2016
Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trialsMehmet Asim Bilen, Amy Patel, Kenneth R Hess, et al.Clinical Breast Cancer|December 3, 2014
Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomesNapa Parinyanitikul, Xiudong Lei, Mariana Chavez-MacGregor, et al.Endocrine-Related Cancer|April 23, 2015
Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumorsArvind Dasari, Alexandria Phan, Sanjay Gupta, et al.Cancer|October 20, 2011
Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situSoley Bayraktar, Nisreen Elsayegh, Angelica M Gutierrez Barrera, et al.Pageof 66